Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study.

Sanne Y Smith-ApeldoornJolien K E VeraartHenricus Gerardus RuheMarije Aan Het RotJeanine KamphuisMarrit K de BoerRobert A Schoevers

Published in: BJPsych open (2021)

These results strengthen the idea that oral esketamine is a safe and well-tolerated treatment for patients with chronic and severe TRD, but therapeutic effects were modest. Results were used to design a randomised controlled trial that is currently in progress.

Keyphrases

low dose
depressive symptoms
high dose
early onset
combination therapy
physical activity